These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35820672)

  • 1. Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea.
    Kim S; Hwang I; Ko M; Kwon Y; Lee YK
    Osong Public Health Res Perspect; 2022 Jun; 13(3):230-237. PubMed ID: 35820672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years.
    Kim S; Heo Y; Seo SY; Lim DS; Cho E; Lee YK
    Osong Public Health Res Perspect; 2022 Oct; 13(5):382-390. PubMed ID: 36328243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021.
    Oh HK; Kim EK; Hwang I; Kim TE; Lee YK; Lee E; Lee YK
    Osong Public Health Res Perspect; 2021 Aug; 12(4):264-268. PubMed ID: 34465075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.
    Hause AM; Gee J; Baggs J; Abara WE; Marquez P; Thompson D; Su JR; Licata C; Rosenblum HG; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1053-1058. PubMed ID: 34351881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
    Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.
    Hwang I; Park K; Kim TE; Kwon Y; Lee YK
    Osong Public Health Res Perspect; 2021 Dec; 12(6):396-402. PubMed ID: 34965689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.
    Ko M; Kim S; Choi SK; Shin SH; Lee YK; Kwon Y
    Osong Public Health Res Perspect; 2024 Aug; 15(4):364-374. PubMed ID: 38988090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea.
    Lee YK; Kwon Y; Heo Y; Kim EK; Kim SY; Cho H; Kim S; Ko M; Lim D; Seo SY; Cho E
    Clin Exp Pediatr; 2023 Oct; 66(10):415-423. PubMed ID: 37309116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Kim S; Ko M; Heo Y; Lee YK; Kwon Y; Choi SK; Bahng E
    Vaccine; 2023 Aug; 41(35):5066-5071. PubMed ID: 37422379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Vaccination in Korea.
    Park WB; Hwang YH; Cheong HJ
    Infect Chemother; 2023 Mar; 55(1):135-149. PubMed ID: 37021429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events with the Pfizer-BioNTech COVID-19 Vaccine among Korean Healthcare Workers.
    Im JH; Kim E; Lee E; Seo Y; Lee Y; Jang Y; Yu S; Maeng Y; Park S; Park S; Kim J; Lee JS; Baek JH
    Yonsei Med J; 2021 Dec; 62(12):1162-1168. PubMed ID: 34816647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data.
    Lee CW; Sa S; Hong M; Kim J; Shim SR; Han HW
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.